Navigation Links
Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
Date:2/7/2013

span>, on Tuesday, February 19, beginning at 11:05 a.m. EST. For more information, see: http://www.stemcellsummit.com/newyork/.

Garr is also scheduled to present at the 7th Annual BIO-Europe Spring Conference 2013, CNS/Neurology track, on Tuesday, March 12, at 9:30 a.m., in Barcelona. For more information, see: http://www.ebdgroup.com/bes/index.php.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed dosing of the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig 's disease, in August 2012; the trial ends six months after that last surgery. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord injury in January 2013.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neuralstem Updates ALS Stem Cell Trial Progress
2. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
3. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
5. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
6. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
7. Neuralstem Announces Proposed Public Offering
8. Neuralstem to Raise $7.0 Million in Registered Direct Offering
9. Nephros Appoints John C. Houghton as President and Chief Executive Officer
10. Herb Baer Appointed President of Polar USA
11. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
(Date:7/30/2015)... Global ENT (Ear, Nose, ... USD 23.01 million in 2022, according to a new ... geriatric population, increasing prevalence of ear, nose, and throat ... among target customer base are expected serve this market ... According to estimates published by the WHO, 15% of ...
(Date:7/30/2015)... 30, 2015  NanoSmart Pharmaceuticals, Inc., a private ... received Orphan Drug Designation from the Food and ... that uses NanoSmart,s proprietary drug delivery platform. The ... the treatment of Ewing,s sarcoma, a rare type ... Orphan Drug Designation on the basis of a ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
(Date:7/30/2015)... NJ (PRWEB) , ... July 30, 2015 , ... ... Jersey's State-designated entity on behalf of the New Jersey Department of Health, has ... Health Information Technology, an agency of the U.S. Department of Health and Human ...
(Date:7/30/2015)... ... July 30, 2015 , ... 1Heart Caregiver Services LLC is offering its ... Make Money in the Booming Homecare Business.” This will be held in its main ... , The event will be hosted by 1Heart’s very own Randy Clarito (Director of ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... After a ... Argus II retinal implant, more commonly known as the “bionic eye,” researchers have determined ... safe and viable tool for patients facing or already affected by complete vision loss ...
(Date:7/30/2015)... Santa Rosa, CA (PRWEB) , ... July 30, 2015 , ... At the presentation of ... topic of discussion was focused on research presented by the Journal of Arthroplasty ... normal tasks – like driving. , Results of the study confirm what Santa ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... for women to ensure their children have the nutrition required to grow into ... by offering discount cards for many prescription pre-natal vitamins. , Folic Acid , ...
Breaking Medicine News(10 mins):Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 2Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 4
... the air, indeed! Today, it has been revealed that deaths ... past decade// and we owe this development to better ... treatment measures. ,The data enabled by the government ... deaths since 1966 for those below 75 years of age. ...
... women with higher levels of Vitamin-E in their blood are ... ,Theresa O. Scholl and colleagues at the University of ... women and measured the plasma concentrations of alpha-tocopherol-one, a form ... pregnancy. ,They found the women who had ...
... Delhi Chief Minister Sheila Dikshit today inaugurated a new 120-bed ... at the Tihar Jail//, one of Asia’s biggest prisons having ... the jail hospital premises, was built at a cost of ... of its kind to be started in any jail in ...
... A team of University of California, San Diego physicists ... of blood vessels// in the brain that makes it ... of the puzzling damage to the brain’s gray matter ... ,In the study, published this week in the ...
... of us think of chromium as the shiny metal in ... the metal plays a crucial role in human health//, reports ... In rats, chromium deficiency leads to high cholesterol levels. In ... information, it’s too early to recommend chromium supplements for cholesterol. ...
... it’s our most vital organ, surprisingly little is ... makes it harder to uncover what’s gone awry ... brain-associated disorders, and ultimately, it often leaves physicians ... as Alzheimer’s and Parkinson’s disease, schizophrenia, attention deficit ...
Cached Medicine News:Health News:Bottleneck in Blood Supply Makes Brain Vulnerable to Strokes 2Health News:Bottleneck in Blood Supply Makes Brain Vulnerable to Strokes 3Health News:Chromium May Help Diabetes, Cholesterol, and Heart Disease 2Health News:Researchers Looking for Genes That Control the Brain 2